Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 3954-3963

  Fu, Maoyong ^a   Maresh, Erin L ^a   Soslow, Robert A ^c   Alavi, Mohammad ^a   Mah, Vei ^a   Zhou, Qin ^c   Iasonos, Alexia ^c   Goodglick, Lee ^a   Gordon, Lynn K ^a,b   Braun, Jonathan ^a   Wadehra, Madhuri ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL MEMBRANE PROTEIN 2; RECOMBINANT ANTIBODY; RECOMBINANT BIVALENT ANTIBODY FRAGMENT A10; RECOMBINANT BIVALENT ANTIBODY FRAGMENT KS49; RECOMBINANT BIVALENT ANTIBODY FRAGMENT KS83; TETRASPANIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MIDDLE AGED; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955104682     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0368     Document Type: Article

References (45)

1. American Cancer Society. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.
2. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol 2009;472:413-37.
3. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198:351-6.
4. Mironov S, Akin O, Pandit-Taskar N, Hann LE. Ovarian cancer. Radiol Clin North Am 2007;45:149-66.
5. Nick AM, Sood AK. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer. Nat Clin Pract Oncol 2008;5:568-9.
6. Visintin I, Feng Z, Longton G, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-72.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
8. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
9. Vasey PA. Ovarian cancer: front-line standard treatment in 2008. Ann Oncol 2008;19 Suppl 7:vii61-6.
10. Wadehra M, Dayal M, Mainigi M, et al. Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouse. Dev Biol 2006;292:430-41.
11. Wadehra M, Mainigi M, Morales SA, et al. Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol 2008;6:15.
12. Dahlin K, Mager EM, Allen L, et al. Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol 2004;31:309-16.
13. Wadehra M, Sulur GG, Braun J, Gordon LK, Goodglick L. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol 2003;74:106-12. (Pubitemid 36438658)
14. Wadehra M, Natarajan S, Seligson DB, et al. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 2006;107:90-8.
15. Shimazaki K, Lepin EJ, Wei B, et al. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 2008;14:7367-77.
16. Hayashi H, Asano R, Tsumoto K, et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother 2004;53:497-509.
17. Kimura N, Kawai S, Kinoshita Y, et al. 2D7 diabody bound to the α2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells. Biochem Biophys Res Commun 2004;325:1201-9.
18. Li X, Stuckert P, Bosch I, Marks JD, Marasco WA. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 2001;8:555-65.
19. Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005;105:562-6.
20. Wadehra M, Goodglick L, Braun J. The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol Biol Cell 2004;15:2073-83.
21. Wadehra M, Iyer R, Goodglick L, Braun J. The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion. J Biol Chem 2002;277:41094-100.
22. Wadehra M, Su H, Gordon LK, Goodglick L, Braun J. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin Immunol 2003;107:129-36. (Pubitemid 36579377)
23. Morales SA, Mareninov S, Wadehra M, et al. FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci 2009;50:462-9.
24. Wadehra M, Forbes A, Pushkarna N, et al. Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev Biol 2005;287:336-45.
25. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
26. Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 2005;4:1605-16.
27. Bast RC, Jr., Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7. (Pubitemid 12235035)
28. Eva A, Robbins KC, Andersen PR, et al. Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature 1982;295:116-9.
29. Wang CX, Wadehra M, Fisk BC, Goodglick L, Braun J. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood 2001;97:3890-5.
30. Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004;18:206-8.
31. Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 2007;67:10484-90.
32. Seligson D, Horvath S, Huerta-Yepez S, et al. Expression of transcription factor Yin Yang 1 in prostate cancer. Int J Oncol 2005;27:131-41.
33. Seligson DB, Hongo F, Huerta-Yepez S, et al. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence. Clin Cancer Res 2007;13:6056-63.
34. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009;174:1619-28.
35. Shen D, Chang HR, Chen Z, et al. Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem Biophys Res Commun 2005;326:218-27.
36. Shen D, Nooraie F, Elshimali Y, et al. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum Pathol 2006;37:1583-91.
37. Liu X, Minin V, Huang Y, Seligson DB, Horvath S. Statistical methods for analyzing tissue microarray data. J Biopharm Stat 2004;14:671-85. (Pubitemid 39296092)
38. Caplan MJ, Kamsteeg EJ, Duffield A. Tetraspan proteins: regulators of renal structure and function. Curr Opin Nephrol Hypertens 2007;16:353-8.
39. Hemler ME. Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov 2008;7:747-58.
40. Shimazaki K, Chan AM, Moniz RJ, et al. Blockade of epithelial membrane protein 2 (EMP2) abrogates infection of Chlamydia muridarum murine genital infection model. FEMS Immunol Med Microbiol 2009;55:240-9.
41. Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res 2007;39:271-8.
42. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC. Models of ovarian cancer - are we there yet? Mol Cell Endocrinol 2005;239:15-26.
43. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 2004;10:1032-42.
44. Latorre IJ, Frese KK, Javier RT. Tight junction proteins and cancer. In: Gonzalez-Mariscal L, editor. Tight junctions. New York: Springer US; 2006, p. 116-34.
45. Olafsen T, Tan GJ, Cheung CW, et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 2004;17:315-23.